Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule

ABSTRACT

The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.

This is a continuation application of U.S. Ser. No. 08/483,316 filedJun. 7, 1995, which issued as U.S. Pat. No. 6,045,802 on Apr. 4, 2002,and which is a continuation-in-part of U.S. Ser. No. 08/317,268 filedOct. 3, 1994, abandoned.

FIELD OF THE INVENTION

The present invention relates to a composition of recombinant viralvector vaccines for the prevention or treatment of pathogenic diseasesand cancer. More particularly, it relates to a composition ofrecombinant viral vectors comprising genes encoding an antigen(s) andrecombinant viral vectors comprising a gene(s) encoding amimmunostimulatory molecule(s). These genes can be inserted into onerecombinant vector or separate viral vectors. Another aspect of thepresent invention is enhancing the immune response against disease cells(such as tumor cells) in a mammal by the infection of these cells with arecombinant vector containing an immunostimulatory gene(s) either insitu, or in vitro and the reintroduction of infected cells into thehost.

BACKGROUND OF THE INVENTION

Attempts to elicit active immune responses in cancer patients to datecan be classified as “non-specific” (i.e., the use of BCG) or“specific”, i.e., the use of tumor cells, tumor cell extracts, mixturesof antigens from cell culture supernatant fluids or oncolysates of tumorcells. The vast majority of these efforts have been pursued in patientswith metastatic melanoma. The development of a recombinant vaccineimplies the use of specific and defined gene products or epitopes of animmunogen or an immunostimulatory molecule. Recombinant vaccines canalso be used for “gene therapy” in that the latter approach requiresusing cells from a given patient and the insertion of a gene for animmunostimulatory molecule such as B7.1, B7.2, IL-2 or GM-CSF into thosecells, either in situ or for administration of cultured cells back tothe patient.

Recombinant vaccines can take many forms. Recombinant proteins can besynthesized by vectors such as baculovirus (an insect vector) or ineukaryotic cells. Synthetic peptides can also serve as immunogens.Peptide vaccines which consist of 9 to several dozen amino acids cantake two forms. They can be mixed with adjuvant or they can be used topulse peripheral blood cells as antigen presenting cells (APCs) forreinfusion into the patient. Recombinant vaccines can also beconstructed by inserting the gene which codes for a given tumorassociated antigen into a vector. Some of the common vectors used arevaccinia virus, avian pox viruses such as fowlpox or canary pox, BCG,adenovirus and Salmonella. These vectors, each with their advantages anddisadvantages are usually employed because of the immunogenicity oftheir constitutive proteins, thus rendering the protein or epitope ofthe inserted gene more immunogenic. Recombinant vaccines can also takethe form of an anti-idiotype antibody which is directed against amonoclonal antibody prepared against a given tumor associated antigen.Most recently, polynucleotide vaccines have been prepared which consistof naked DNA of a tumor associated gene in a plasmid containing apromoter gene. Whereas all of the above have been analyzed in animalmodels, very few studies have compared relative efficiencies of oneapproach versus the other. Clinical trials have now begun using some ofthese approaches in breast cancer and other carcinoma patients andothers will most likely begin in the near future.

There are several antigens that have now been identified for potentialuse in recombinant vaccines for cancer therapies. The first of these isthe c-erbB/2 oncogene which is found to be over expressed inapproximately 20-30% of breast tumors (Pietras R J et al. Oncogene(9:1829-1838, 1994). It has been shown (Bernards R et al. Proc. Natl.Acad. Sci. USA 84:6854-6858, 1987) that the point mutated c-erbB/2oncogene in rats, when inserted into vaccinia virus, is immunogenic andcan lead to anti-tumor effects. The human c-erbB/2, however, is notmutated. It has recently been shown (Disis M L et al., Cancer Res.54:1071-1076, 1994)), that this gene contains several epitopes whichappear to generate human T-cell responses in vitro. The point mutatedp53 oncogene, also found in many human breast tumors has been shown tobe a potential target for cytotoxic T-cells (Yanuck M et al. Cancer Res.53:3257-3261, 1993). Clinical studies are now beginning in whichpeptides reflecting specific point mutations are being pulsed with humanperipheral blood lymphocytes (PBLs) and readministered to patients. Thebreast cancer mucin, MUC-1 or DF3, represents a differentiation antigenof the breast (Abe M and Kufe D, Proc. Natl. Acad. Sci. USA 90:282-286,1993). While MUC-1 is expressed in a range of normal epithelial tissues,it appears to be uniquely glycosylated in breast cancer tissue. Thetandem repeat of the core protein of the MUC-1 mucin has been reportedto be immunogenic in humans (Barnd D L et al., Proc. Natl. Acad. Sci.USA 86:7159-7163, 1989) in that lymph nodes of breast cancer patientscontain T-cells which can be activated by MUC-1 peptides in an non-MHCrestricted manner. It has also been shown (Rughetti A et al., CancerRes. 53:2457-2459, 1993) that ovarian cancer patients can make antibodyresponses to this region. Animal models in which the MUC-1 gene has beeninserted into vaccinia virus have been reported (Hareuveni M et al.,Proc. Natl. Acad. Sci. USA 87:9498-9502, 1990; Hareuveni et al., Vaccine9:618-626, 1991). A clinical trial in which MUC-1 peptide is beingpulsed with human PBLs is currently underway in breast cancer patients.Another mucin that represents a potential target for cancer therapy isTAG-72 which is found on approximately 70-80% of human breast cancers(Thor A et al., Cancer Res. 46:3118-3124, 1986).

Most attempts at active immunization against cancer antigens haveinvolved whole tumor cells or tumor cell fragments, though it would bemost desirable to immunize specifically against unique tumor antigensthat distinguish malignant from normal cells. The molecular nature ofthe tumor associated antigens recognized by T lymphocytes is poorlyunderstood. In contrast to antibodies that recognize epitopes or intactproteins, T cells recognize short peptide fragments (8-18 amino acids)that are present on cell surface class I or II major histocompatibility(MHC) molecules and it is likely that tumor associated antigens arepresented and recognized by T cells in this fashion.

A number of genes have been identified that encode melanoma tumorantigens recognized by TIL in the context of the HLA-A2 class I molecule(Kawakami Y. et al. Proc. Natl. Acad. Sci. USA 91:3515-3519, 1994;Kawakami Y. et al. J. Exp. Med 180:347-352, 1994; Kawakami Y. et al.Cancer Res. 54:3124-3126, 1994).

The human carcinoembryonic antigen (CEA) also represents a potentialtarget molecule for the immunotherapy of a range of human carcinomasincluding colorectal, gastric, pancreatic, breast, and non-small cellcarcinomas (Robbins P F et al., Int. J. Cancer 53:892-897, 1993; EstebanJ M et al., Cancer 74:1575-1583, 1994). Experimental studies have shownthat anti-idiotype antibodies directed against anti-CEA monoclonalantibodies can elicit immune responses in mice (Bhattacharya-ChatterjeeM et al., Int. Rev. Immuno. 7:289-302, 1991). Clinical studies usingthis anti-idiotype antibody are currently in progress. A recombinantvaccine has also been developed in which the CEA gene has been insertedinto vaccinia virus (Kantor J. et al., J. Natl. cancer Inst.84:1084-1091, 1992). A Phase I clinical trial involving this vaccine hasjust been completed.

The identification of an immunodominant peptide that represents a uniquetumor antigen has opened new possibilities for immunization againstcancer. Substantial evidence exists in animal models that immunizationwith immunodominant viral peptides can induce viral specific CTL thatcan confer protection against viral infection. Although pure peptidealone is ineffective in stimulating T cell responses, peptidesemulsified in adjuvants or complexed with lipids have been shown toprime mice against challenge with fresh virus and can induce virusspecific CTL that protect mice against lethal viral inocula (Kast, W. M.et al Proc. Nat'l Acad. Sci. U.S.A. 88:2283-2287, 1991; Deres, K. et alNature 342:561-564, 1989; Gao, X. M. et al J. Immunol. 147:3268-3273,1991; Aichele, P. J. Exp. Med. 171:1815-1820, 1990; Collins, D. S. et alJ. Immunol. 148:3336-3341, 1992). Immunization of mice againstsplenocytes coated with Listeria monocytogenes peptide epitopes alsoresults in the generation of Listeria specific CTL which can be expandedin culture. Adoptive transfer of these CTL can protect mice againstlethal bacterial challenge (Harty, J. T. et al J. Exp. Med.175:1531-1538, 1992). Peptides representing antigenic epitopes of HIVgp120 and gp160 emulsified in complete Freund's adjuvant can also primespecific CTL responses (Takahashi, H. et al Proc. Nat'l Acad. Sci.U.S.A. 85:3105-3109, 1988; Hart, M. K. et al Proc. Nat'l Acad. Sci.U.S.A. 88:9448-9452, 1991).

While immunization with peptides in adjuvants or complexed with lipidsgives rise to T cell responses in mice, the reactions are rarely strongenough to induce T reactive cells in primary splenocytes. The detectionof sensitized lymphocytes almost invariably requires secondary in vitrostimulation.

The expression of the B7 gene family has been shown to be an importantmechanism of antitumor responses in both mice and humans. It is nowbecoming apparent that at least two signals are required for activationof naive T-cells by antigen bearing target cells: an antigen specificsignal, delivered through the T-cell receptor, and an antigenindependent or costimulatory signal leading to lymphokine products(Hellstrom, K. E. et al. Annals NY Acad. Sci. 690:225-230, 1993). Twoimportant costimulatory molecules are B7-1, which is the ligand forT-cell surface antigens CD28 and CTLA4 (Schwartz, R. H. Cell71:1065-1068, 1992; Chen, L. et al. Cell 71:1093-1102, 1992; Freeman, G.J. et al. J. Immunol 143:2714-2722, 1989; Freeman, G. J. et al. J. Exp.Med. 174:625-631, 1991), and B7-2, an alternative ligand for CTLA4(Freeman, G. J. et al. Science 262:813-960, 1993). To date, both murineB7-1 and B7-2 (Freeman, G. J. et al. J. Exp. Med. 174:625-631, 1991;Freeman, G. J. et al. Science 262:813-960, 1995) and human B7-1 and B7-2have been described (Freeman, G. J. et al. J. Immunol 143:2714-2722,1989; Freeman, G. J. et al Science 262:909-911, 1993). It is unclear atthis time whether the costimulatory signals provided by B7-1 and B7-2are functionally distinct or redundant mechanisms for T-cell activation(Hathcock, K. S. et al. J. Exp. Med. 180:631-640, 1994). Most murine andhuman tumors do not express B7-1 or B7-2, implying that even when atumor expresses a potential rejection antigen, it is unlikely toactivate antitumor T-cell responses (Hellstrom, K. E. et al Annals. N.Y.Acad. Sci. 690:225-230, 1993); Hellstrom, I. Annals. N.Y. Acad. Sci.690:24-31, 1993). In essence, anergy may result from only one signalbeing received by the T-cell (Hellstrom, K.e. et al. Annals. N.Y. Acad.Sci. 690:225-230, 1993. Transfection of B7 into melanoma cells was foundto induce the rejection of a murine melanoma in vivo (Townsend, S. E. etal Science 259:368-370, 1993).

Vaccinia viruses have been extensively used in humans and the use of avaccina based vaccine against smallpox has led to the worldwideeradication of this disease (reviewed in reference Moss, B. Science252:1662-1667, 1991). Vaccinia viruses have the advantages of low cost,heat stability and a simple method of administration. Attempts have beenmade to develop vaccinia virus vectors for the prevention of otherdiseases.

Vaccina virus is a member of the pox virus family of cytoplasmic DNAviruses. DNA recombination occurs during replication of pox viruses andthis has been used to insert DNA into the viral genome. Recombinantvaccina virus expression vectors have been extensively described. Thesevectors can confer cellular immunity against a variety of foreign geneproducts and can protect against infectious diseases in several animalmodels. Recombinant vaccina viruses have been used in human clinicaltrials as well. Cooney et al immunized 35 healthy HIV seronegative maleswith a recombinant vaccinia virus expressing the gp160 envelope gene ofHIV (Cooney, E. The Lancet 337:567-572, 1991). Graham et al randomized36 volunteers to receive either recombinant vaccinia virus containingthe gp160 HIV envelope protein or control vaccinia virus (Graham, B. S.et al J. Infect. Dis. 166:244-252, 1992). Phase I studies usingrecombinant vaccinia virus have begun in patients with metastaticmelanoma using a recombinant virus expressing the p97 melanoma antigen(Estin, C. D. et al Proc. Nat'l Acad. Sci. 85:1052-1056, 1988) and aPhase I trial to use recombinant vaccinia virus expressing the humancarcinoembryonic antigen in patients with advanced breast, lung orcolorectal carcinoma has just been completed. In these trials, vacciniavirus is administered by intradermal scarification and side effects havebeen minimal including local skin irritation, lymphadenopathy andtransient flu-like symptoms.

Fowlpox and canarypox viruses are members of the pox virus family(avipox virus genes). These viruses will only replicate in avian cellsand cannot replicate in human cells. They are cytoplasmic viruses thatdo not integrate into the host genome but are capable of expression of alarge number of recombinant genes in eukaryotic cells.

Recombinant avian pox virus expressing rabies glycoprotein has been usedto protect mice, cats and dogs against live rabies virus challenge.Immunization of chickens and turkeys with a recombinant avian poxexpressing the influenza HA antigen protected against a lethal challengewith influenza virus (Taylor et al., Vaccine 6:504-508, 1988). Canarypoxvolunteers received doses up to 10^(5.5.) infectious units (Cadoz M., etal., The Lancet 339: 1429-1432, 1992). In a recent trial sponsored byNIAID (Protocol 012A: A Phase I safety and immunogenicity trial of liverecombinant canarypox-gp 160 MN (ALVAC VCP125 HIV-1gp160MNO in HIV-1uninfected adults) patients received recombinant canarypox viruscontaining the HIV gp160 gene by intramuscular injection at doses up to10^(5.5) pfu with little or no toxicity (personal communication, P.Fast, NIAID).

Avian pox viruses thus represent attractive vehicles for immunizationsince they can stimulate both humoral and cellular immunity, can beeconomically produced in high titer (10⁹ pfu/ml) and yet their inabilityto productively infect human cells substantially increases the safety oftheir use.

Another considerable advantage of avian pox virus is that there may belittle or no cross-reactivity with vaccinia virus and thus previouslyvaccinated humans may not have pre-existing immune reactivity to fowlpoxvirus proteins.

SUMMARY OF THE INVENTION

The present invention relates to a composition of recombinant viralvector vaccines for the prevention or treatment of pathogenic diseasesand cancer. More particularly, it relates to a composition ofrecombinant viral vectors comprising genes encoding an antigen(s) andrecombinant viral vectors comprising a gene(s) encoding animmunostimulatory molecule(s). These genes can be inserted into onerecombinant vector or separate viral vectors. Another aspect of thepresent invention is enhancing the immune response against disease cells(such as tumor cells) in a mammal by the infection of these cells with arecombinant vector containing an immunostimulatory gene(s) either insitu, or in vitro and the reintroduction of infected cells into thehost.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other objects, feature and many of the attendant advantages ofthe invention will be better understood upon a reading of the detaileddescription of the invention when considered.

FIGS. 1A-1D shows Fluorescent Analysis of BSC-1 cells expressing rV-B7proteins. BSC-1 cells were stained for either B7-1 or B7-2 surfaceproteins before infection (FIG. 1A), after infection with either 10 MOIV-Wyeth (FIG. 1B), rV-B7-1 (FIG. 1C), or rV-B7-2 (FIG. 1D). FIGS. 1A and1B are representative of B7 staining on normal BSC-1 cells or cellsinfected with the parent vaccinia strain used to construct rV-B7-1 andrV-B7-2, while FIGS. 1C and 1D illustrate strong expression ofrecombinant B7 proteins after infection with rV-B7-1 or rV-B7-2, usingmonoclonal antibodies specific for these molecules, respectively.

FIGS. 2A-2D shows growth of transplanted mouse adenocarcinoma cellsexpressing rV-B7 proteins. Five C57BL/6 mice per group were injectedwith 3×10⁵ MC38 cells that were uninfected (FIG. 2A), infected with 0.25MOI V-Wyeth (FIG. 2B), rV-B7-1 (FIG. 2C), or rV-B7-2 (FIG. 2D). FIGS. 2Aand 2B illustrate normal growth rates of MC38 cells. FIGS. 2C and 2Dillustrate growth rates of MC38 cells expressing recombinant B7proteins. Tumors were measured in two dimensions. These experiments wererepeated 3 additional times with similar results. *Animal grew anintraperitoneal tumor which could not be measured.

FIGS. 3A-3C. FIG. 3A shows growth of uninfected MC38 tumors in naiveC57BL/6 mice. FIG. 3B shows growth of MC38 tumors in mice previouslyadministered (day 40) with MC38 cells infected with rV-B7-1 andchallenged with 3×10⁵ MC38 cells. FIG. 3C shows growth of MC38 tumors inmice previously administered (day 40) with MC38 cells infected withrV-B7-2 and challenged with 3×10⁵ MC38 cells.

FIG. 4 shows each treatment group of 5 C57BL/6 mice immunized withrecombinant vaccinia viruses encoding the genes for either humancarcinoembryonic antigen gene (rV-CEA), murine B7-2 (rV-B7), or the wildtype strain of vaccinia virus (V-Wyeth). Each mouse was administered1×10⁷ plaque forming units by tail scarification in the followingratios: 1:1 rV-CEA/rV-B7 (5×10⁶ PFU rV-CEA+5×10⁶ PFU rV-B7); 1:1V-Wyeth/rV-B7 (5×10⁶ PFU V-Wyeth+5×10⁶ PFU rV-B7); or 1:1 rV-CEA/V-Wyeth(5×10⁶ PFU rV-CEA+5×10⁶ PFU V-Wyeth). Three spleens were removed andpooled from each treatment group 14 days after immunization and astandard 5 day lymphoproliferative assay was performed as previouslydescribed (Kantor, et al. JNCI, 84:1084, 1992). Purified T cells weretested for their proliferative capacity against a Baculovirus producedrecombinant CEA at 100 μg/ml. Stimulation index was calculated inrelationship to the cells reactivity to media (background).

FIG. 5 shows each treatment group of 5 C57BL/6 mice immunized withrecombinant vaccinia viruses encoding the genes for either humancarcinoembryonic antigen gene (rV-CEA), murine B7-2 (rV-B7), or the wildtype strain of vaccinia virus (V-Wyeth). Each mouse was administered1×10⁷ plaque forming units by tail scarification in the followingratios: 1:3 rV-CEA/rV-B7 (2.5×10⁶ PFU rV-CEA+7.5×10⁶ PFU rV-B7); 1:3V-Wyeth/rV-B7 (2.5×10⁶ PFU V-Wyeth+7.5×10⁶ PFU rV-B7); or 1:3rV-CEA/V-Wyeth (2.5×10⁶ PFU rV-CEA+7.5×10⁶ PFU V-Wyeth). Three spleenswere removed and pooled 14 days after immunization and a standard 5 daylymphoproliferative assay was performed as previously described (Kantor,et al. JNCI, 84:1084, 1992). Purified T-cells were tested for theirproliferative capacity against a Baculovirus produced recombinant CEA at100 μg/ml. Stimulation index was calculated in relationship to the cellsreactivity to media (background).

FIGS. 6A-6D show the fluorescent analysis of BSC-1 cells co-infectedwith rV-CEA and rV-B7. BSC-1 cells were co-infected with virus at an MOIof 5 in ratios of either: 6A) V-Wyeth; 6B) rV-CEA:V-Wyeth (3:1); 6C)Wyeth:rV-B7 (3:1); or 6D) rV-CEA:rV-B7 (3:1) and stained with MAbsPE-B7-1 and FITC-COL-1. X and Y axes represent CEA and B7-1 fluorescencerespectively, while the Z axis represents cell number. Percentages ofpositive cells in each quadrant are depicted in inset panels. FIG. 6Adepicts staining on normal BSC-1 cells infected with the parent vacciniastain. FIGS. 6B and 6C depict expression of CEA or B7-1 during singleinfections, while FIG. 6D illustrates co-expression of both recombinantmolecules following infection with both rV-CEA and rV-B7.

FIG. 7 shows enhancement of primary CTL activity following immunizationwith rV-CEA and/or rV-B7. Cytotoxic activity specific for CEA wasanalyzed 10 days following immunization with a total of 1×10⁷ PFU ofeither rV-CEA:V-Wyeth (3:1; triangles) or rV-CEA:rV-B7 (3:1; circles).Splenic T-cells from each group were incubated with either MC38 cells(CEA negative; closed symbols) or MC-38-CEA-2 cells (CEA positive; opensymbols) in a 16 hour cytotoxic assay. Anti-V-Wyeth CTL activitywas >50% in all samples (data not shown).

FIGS. 8A-8D show growth of transplanted mouse adenocarcinoma cellsexpressing CEA in mice immunized with rV-CEA and rV-B7. 10C57BL/6 miceper group were immunized one time with a total of 10⁷ PFU of either 8A)V-Wyeth; 8B) rV-CEA:V-Wyeth (3:1); 8C) Wyeth:rV-B7 (3:1); or 8DrV-CEA:rV-B7 (3:1), and injected 14 days later with 3×10⁵ MC-38-CEA-2cells subcutaneously.

FIGS. 9A-9B show antitumor immunity in mice previously receiving amixture of rV-B7 and rV-CEA. FIG. 9A shows growth of MC-38-CEA-2 tumorsin naive C57BL/6 mice, and tumor growth in mice surviving previous tumorchallenge (FIG. 9B). Mice were immunized with rV-CEA:rV-B7 (3:1), andchallenged with tumor 14 days later. Mice remaining tumor free after 60days (FIG. 8D), were rechallenged on the opposite flank (FIG. 9B).

FIG. 10 shows enhancement of primary CTL activity following immunizationwith rV-PSA and rV-B7-1. Cytotoxic activity specific for PSA wasanalyzed 10 days following immunization with a total of 1×10⁷ PFU ofrV-PSA, rV-PSA:rV-B7-1 or rV-CEA:r-B7-1. Splenic T-cells from each groupwere incubated with either MC38 cells or MC38-PSA cells in a 16 hourcytotoxic assay.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is a composition comprising a novel recombinantvirus expressing an antigen(s) from a disease causing agent or diseasestate and a recombinant virus expressing an immunostimulatorymolecule(s) or genes coding for both molecules inserted in the samevector composition is capable of eliciting and/or upregulating an immuneresponse in a mammal to T-dependent antigens or antibodies for thepurpose of preventing or treating a disease. The composition of thepresent invention is particularly important in upregulatingcell-mediated immunity as well as antibodies.

Cell-mediated immunity is crucial to resistant diseases caused by cancerand pathogenic microorganisms, particularly viruses and otherintracellular microorganisms. The composition of the present inventionhas a first recombinant virus which has incorporated into its genome orportion thereof a gene encoding an antigen from cells of a disease stateand a second recombinant virus which has one or more genes encoding oneor more immunostimulatory molecules or genes coding for both moleculesinserted into the same vector. A host cell infected with bothrecombinant viruses expresses both the antigen(s) from a disease causingagent and expresses the immunostimulatory molecule(s). The antigen maybe expressed at the cell surface of the infected host cell. Theimmunostimulatory molecule may be expressed at the cell surface or maybe actively secreted by the host cell.

The expression of both the antigen and the immunostimulatory moleculeprovides the necessary MHC restricted peptide to specific T cells andthe appropriate signal to the T cell to aid in antigen recognition andproliferation or clonal expansion of antigen specific T cells. Theoverall result is an upregulation of the immune system. In a preferredembodiment the upregulation of the immune response is an increase inantigen specific T-helper lymphocytes and/or cytotoxic lymphocytes,which are able to kill or inhibit the growth of a disease causing agentor a cell infected with a disease causing agent.

In one embodiment, the composition comprises a recombinant viruscomprising the virus genome or portions thereof and a nucleic acidsequence encoding an antigen from a pathogenic microorganism and arecombinant virus comprising one or more nucleic acid sequences encodingone or more immunostimulatory molecules.

In another embodiment, the composition comprises a recombinant viruscomprising the virus genome or portions thereof and the nucleic acidsequence encoding a tumor associated antigen, and a recombinant virusencoding one or more nucleic acid sequences encoding one or moreimmunostimulatory molecules.

In one embodiment the recombinant viruses have been constructed toexpress cytokines (TNF-α, IL-6, GM-CSF, and IL-2), and co-stimulatoryand accessory molecules (B7-1, B7-2) alone and in a variety ofcombinations. Simultaneous production of an immunostimulatory moleculeand the model TAA at the site of virus replication/infection (in anycase, the site of TAA production) enhances the generation of specificeffectors. Dependent upon the specific immunostimulatory molecules,different mechanisms might be responsible for the enhancedimmunogenicity: augmentation of help signal (IL-2), recruitment ofprofessional APC (GM-CSF), increase in CTL frequency (IL-2), effect onantigen processing pathway and MHC expression (IFNγ and TNFα) and thelike. The co-expression of a model antigen together with at least oneimmunostimulatory molecule is effective in an animal model to showanti-tumor effects.

In some cases it may be beneficial to make a recombinant viruscomprising more than one antigen of interest for the purpose of having amultivalent vaccine. For example, the recombinant virus may comprise thevirus genome or portions thereof, the nucleic acid sequence encodingGP120 (from HIV) and the nucleic acid sequence encoding Hep B surfaceantigen.

In one embodiment, the composition comprises a recombinant viruscomprising a vaccinia virus genome or portions thereof, the nucleic acidsequence encoding CEA and a recombinant virus comprising the nucleicacid sequence encoding the immunostimulatory molecule, B 7.1 alone or incombination with the nucleic acid sequence encoding theimmunostimulatory molecule, B7.2, or a recombinant virus containing boththe genes for a tumor antigen and a immunostimulatory molecule.

The present invention also encompasses a recombinant virus comprisingthe virus genome or portion thereof, and one or more nucleic acidsequences encoding one or more B7 molecules, preferably a recombinantvaccinia virus expressing B7-1 and/or B7-2. The rapid infection of tumorcells with these recombinant viruses demonstrates that vaccinia canauthentically express these proteins and that they are functionalmolecules. Weakly immunogenic syngeneic tumors expressing theserecombinant molecules are rejected by immunocompetent hosts.

In a specific embodiment recombinant virus is a recombinant vacciniavirus containing B7.1 and a recombinant vaccinia virus containing B7.2(designated rV-B7-1 and rV-B7-2, respectively).

In one embodiment the composition comprises rV-B7-1 and/or rV-B7.2 incombination with rV-CEA. The B7 molecule includes but is not limited toB7-1, B7-2 and the like and analogs thereof. The B7 gene may be clonedfrom mammalian sources, including but not limited to mammalian tissues,genomic libraries or cDNA libraries, preferably from murine or humansources.

Virus Vectors

Virus that may be used in the present invention are those in which aportion of the genome can be deleted to introduce new genes withoutdestroying infectivity of the virus. The virus vector of the presentinvention is a nonpathogenic virus. In one embodiment the virus vectorhas a tropism for a specific cell type in the mammal. In anotherembodiment, the virus vector of the present invention is able to infectprofessional antigen presenting cells such as dendritic cells andmacrophages. In yet another embodiment of the present invention, thevirus vector is able to infect any cell in the mammal. The virus vectormay also infect tumor cells.

The virus of the present invention include but is not limited toPoxvirus such as vaccinia virus, fowlpox virus and a highly attenuatedvaccinia virus (MVA), adenovirus, baculovirus and the like.

The vaccinia virus genome is known in the art. It is composed of a HINDF13L region, TK region, and an HA region. The recombinant vaccinia virushas been used in the art to incorporate an exogenous gene for expressionof the exogenous gene product (Perkus et al. Science 229:981-984, 1985;Kaufman et al. Int. J. Cancer 48:900-907, 1991; Moss Science 252:1662,1991).

A gene encoding an antigen of a disease state or disease causing agentmay be incorporated into the HIND F13L region or alternativelyincorporated into the TK region of recombinant vaccinia virus vector orother nonessential regions of the vaccinia virus genome. Likewise, agene encoding an immunostimulatory molecule may be incorporated into theHIND F13L region or the TK region of recombinant vaccinia virus vector.

Sutter and Moss (Proc. Nat'l. Acad. Sci U.S.A. 89:10847-10851, 1992) andSutter et al. (Virology 1994) disclose the construction and use as avector, the non-replicating recombinant Ankara virus (MVA, modifiedvaccinia Ankara) which may be used as a viral vector in the presentinvention.

Baxby and Paoletti (Vaccine 10:8-9, 1992) disclose the construction anduse as a vector, of the non-replicating poxvirus, including canarypoxvirus, fowlpox virus and other avian species which may be used as aviral vector in the present invention.

Expression vectors suitable for use in the present invention comprise atleast one expression control element operationally linked to the nucleicacid sequence. The expression control elements are inserted in thevector to control and regulate the expression of the nucleic acidsequence. Examples of expression control elements includes, but is notlimited to, lac system, operator and promoter regions of phage lambda,yeast promoters and promoters derived from polyoma, adenovirus,retrovirus or SV40. Additional preferred or required operationalelements include, but are not limited to, leader sequence, terminationcodons, polyadenylation signals and any other sequences necessary orpreferred for the appropriate transcription and subsequent translationof the nucleic acid sequence in the host system. It will be understoodby one skilled in the art the correct combination of required orpreferred expression control elements will depend on the host systemchosen. It will further be understood that the expression vector shouldcontain additional elements necessary for the transfer and subsequentreplication of the expression vector containing the nucleic acidsequence in the host system. Examples of such elements include, but arenot limited to, origins of replication and selectable markers. It willfurther be understood by one skilled in the art that such vectors areeasily constructed using conventional methods (Ausubel et al., (1987) in“Current Protocols in Molecular Biology”, John Wiley and Sons, New York,N.Y.) or commercially available.

Disease Causing Agents

The recombinant virus of the present invention is effective in treatingor preventing disease caused by disease causing agents. Each diseasecausing agent or disease state has associated with it an antigen orimmunodominant epitope on the antigen which is crucial in immunerecognition and ultimate elimination or control of the disease causingagent or disease state in a host, sometimes referred to in the art as aprotective antigen. The host immune system must come in contact with theantigen or immunodominant epitope on the antigen in order to mount ahumoral and/or cellular immune response against the associated diseasecausing agent.

The composition of the present invention comprises a recombinant virusof the present invention comprises one or more nucleic acid sequencesencoding one or more isolated antigens or immunodominant epitopes and asecond recombinant virus comprises one or more immunostimulatorymolecules.

Such disease causing agents include but are not limited to cancer andpathogenic microorganisms. Cancers which may be treated using therecombinant virus of the present invention include but are not limitedto primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lungcancer, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma,leukemias, uterine cancer, and adenocarcinomas such as breast cancer,prostate cancer, ovarian cancer, pancreatic cancer and the like.

The aforementioned cancers can be assessed or treated by methodsdescribed in the present application. In the case of cancer, a geneencoding an antigen associated with the cancer is incorporated into therecombinant virus genome or portion thereof along with a gene encodingone or more immunostimulatory molecules. Alternatively, the geneencoding an antigen associated with the cancer and the gene encoding oneor more immunostimulatory molecules are incorporated into separaterecombinant viruses. The antigen associated with the cancer may beexpressed on the surface of a cancer cell or may be an internal antigen.In one embodiment the antigen associated with the cancer is a tumorassociated antigen (TAA) or portion thereof. Examples of TAA that may beused in the present invention include but are not limited to melanomaTAAs which include but are not limited to MART-1 (Kawakami et al. J.Exp. Med. 180:347-352, 1994), MAGE-1, MAGE-3, GP-100, (Kawakami et al.Proc. Nat'l. Acad. Sci. U.S.A. 91:6458-6462, 1994), CEA and tyrosinase(Brichard et al. J. Exp. Med. 178:489, 1993).

In another embodiment the TAAs are MUC-1, MUC-2, the point mutated rasoncogene and the point mutated p53 oncogenes (pancreatic cancer), CA-125(ovarian cancer), PSA (prostate cancer), c-erb/B2 (breast cancer) andthe like (Boon et al., Ann. Rev. Immunol. 12:337, 1994).

The present invention is in no way limited to the genes encoding theabove listed TAAs. Other TAAs may be identified, isolated and cloned bymethods known in the art such as those disclosed in U.S. Pat. No.4,514,506.

Genes encoding an antigen of a disease causing agent in which the agentis a pathogenic microorganism include viruses such as HIV (GP-120, p17,GP-160 antigens), influenza (NP, HA antigen), herpes simplex (HSVdDantigen), human papilloma virus, equine encephalitis virus, hepatitis(Hep B Surface Antigen) and the like. Pathogenic bacteria include butare not limited to Chlamydia, Mycobacteria, Legioniella and the like.Pathogenic protozoans include but are not limited to malaria, Babesia,Schistosomiasis and the like. Pathogenic yeast include Aspergillus,invasive Candida, and the like. In a preferred embodiment the pathogenicmicroorganism is an intracellular organism.

Immunostimulatory Molecules: Costimulation/Accessory Molecules andCytokines

The gene from costimulation/accessory molecule and/or gene encoding an acytokine is incorporated into the genome of a recombinant virus.Examples of costimulation molecules include but are not limited to B7-1,B7-2, ICAM-1, LFA-3, CD72 and the like. Examples of cytokinesencompassed by the present invention include but are not limited toIL-2, GM-CSF, TNFα, IFNγ, IL-12, RANTES, and the like.

IL-2 construct

The IL-2 gene of the present invention is made as disclosed by Taniguchiet al (Nature 302:305, 1983).

B7 Construct

Co-stimulatory molecules of the B7 family (namely B7.1, B7.2, andpossibly B7.3) represent a more recently discovered, but important groupof molecules. B7.1 and B7.2 are both member of the Ig gene superfamily.These molecules are present on macrophages, dendritic cells, monocytes,i.e., antigen presenting cells (APCs). If a lymphocyte encounters anantigen alone, with co-stimulation by B7. 1, it will respond with eitheranergy, or apoptosis (programmed cell death); if the co-stimulatorysignal is provided it will respond with clonal expansion against thetarget antigen. No significant amplification of the immune responseagainst a given antigen occurs without co-stimulation (June et al.(Immunology Today 15:321-331, 1994); Chen et al. (Immunology Today14:483-486); Townsend et al. (Science 259:368-370)). Freeman et al. (J.Immunol. 143:2714-2722, 1989) report cloning and sequencing of B7.1gene. Azuma et al. (Nature 366:76-79, 1993) report cloning andsequencing B7.2 gene.

In one embodiment the B7.1 gene or the B7.2 gene was inserted intovaccinia virus. In another embodiment, the CEA gene and the IL-2 genewere both inserted into a single vaccinia virus. The rV-CEA/_(n)IL-2(ATCC Designation VR 2480), rV-CEA-T108 (ATCC Designation No. VR 2481),rV-_(m)B7-2 (ATCC Designation VR 2482); and rV-_(m)B7-1 (ATCCDesignation VR 2483) were deposited with the American Type CultureCollection (ATCC), 12301 Parklawn Drive, Rockville, Md. on Oct. 3, 1994under the terms of the Budapest Treaty.

The present invention also encompasses methods of treatment orprevention of a disease caused by the disease causing agents or diseasestates disclosed here.

In the method of treatment, the administration of the recombinant virusof the invention or composition of recombinant viruses may be for either“prophylactic” or “therapeutic” purpose. When provided prophylactically,the recombinant virus or composition of recombinant viruses of thepresent invention is provided in advance of any symptom. Theprophylactic administration of the recombinant virus or composition ofrecombinant viruses serves to prevent or ameliorate any subsequentinfection or disease. When provided therapeutically, the recombinantvirus or composition of more than one recombinant virus is provided at(or shortly after) the onset of a symptom of infection or disease. Thusthe present invention may be provided either prior to the anticipatedexposure to a disease causing agent or disease state or after theinitiation of the infection or disease.

The genetic definition of tumor-specific antigens allows for thedevelopment of targeted antigen-specific vaccines for cancer therapy.Insertion of a tumor antigen gene in the genome of viruses incombination with a recombinant virus comprising an immunostimulatorymolecule is a powerful system to elicit a specific immune response interms of prevention in patient with an increased risk of cancerdevelopment (preventive immunization), prevention of disease recurrenceafter primary surgery (anti-metastatic vaccination), or as a tool toexpand the number of CTL in vivo, thus improving their effectiveness ineradication of diffuse tumors (treatment of established disease).Finally, recombinant viruses or composition of the present invention canelicit an immune response in patient that is enhanced ex vivo prior tobeing transferred back to the tumor bearer (adoptive immunotherapy).

The term “unit dose” as it pertains to the inoculum refers to physicallydiscrete units suitable as unitary dosages for mammals, each unitcontaining a predetermined a quantity of recombinant virus calculated toproduce the desired immunogenic effect in association with the requireddiluent. The specifications for the novel unit dose of an inoculum ofthis invention are dictated by and are dependent upon the uniquecharacteristics of the recombinant virus and the particular immunologiceffect to be achieved.

The inoculum is typically prepared as a solution in tolerable(acceptable) diluent such as saline, phosphate-buffered saline or otherphysiologically tolerable diluent and the like to form an aqueouspharmaceutical composition.

The route of inoculation may be intravenous (I.V.), intramuscular(I.M.), subcutaneous (S.C.), intradermal (I.D.) and the like, whichresults in eliciting a protective response against the disease causingagent. The dose is administered at least once. Subsequent doses may beadministered as indicated.

In providing a mammal with the recombinant virus of the presentinvention, preferably a human, the dosage of administered recombinantvirus will vary depending upon such factors as the mammal's age, weight,height, sex, general medical condition, previous medical history,disease progression, tumor burden and the like.

In general, it is desirable to provide the recipient with a dosage ofeach recombinant virus in the composition in the range of from about 10⁵to about 10¹⁰ plaque forming units/mg mammal, although a lower or higherdose may be administered.

The composition of recombinant viral vectors can be introduced into amammal either prior to any evidence of cancers such as melanoma or tomediate regression of the disease in a mammal afflicted with a cancersuch as melanoma. Examples of methods for administering the compositioninto mammals include, but are not limited to, exposure of cells to therecombinant virus ex vivo, or injection of the composition into theaffected tissue or intravenous, S.C., I.D. or I.M. administration of thevirus. Alternatively the recombinant viral vector or combination ofrecombinant viral vectors may be administered locally by directinjection into the cancerous lesion or topical application in apharmaceutically acceptable carrier. The quantity of recombinant viralvector, carrying the nucleic acid sequence of one or more TAAs to beadministered is based on the titer of virus particles. A preferred rangeof the immunogen to be administered is 10⁵ to 10¹⁰ virus particles permammal, preferably a human.

In the case where a combination of a first recombinant viral vectorcarrying a nucleic acid sequence of one or more TAAs and a secondrecombinant viral vector carrying the nucleic acid sequence of one ormore immunostimulatory molecules is used, the mammal may be immunizedwith different ratios of the first and second recombinant viral vector.In one embodiment the ratio of the first vector to the second vector isabout 1:1, or about 1:3, or about 1:5. Optimal ratios of the firstvector to the second vector may easily be titered using the methodsdescribed herein.

After immunization the efficacy of the vaccine can be assessed byproduction of antibodies or immune cells that recognize the antigen, asassessed by specific lytic activity or specific cytokine production orby tumor regression. One skilled in the art would know the conventionalmethods to assess the aforementioned parameters. If the mammal to beimmunized is already afflicted with cancer or metastatic cancer thevaccine can be administered in conjunction with other therapeutictreatments.

In one method of treatment, autologous cytotoxic lymphocytes or tumorinfiltrating lymphocytes may be obtained from a patient with cancer. Thelymphocytes are grown in culture and antigen specific lymphocytesexpanded by culturing in the presence of specific antigen and cytokine.The antigen specific lymphocytes are then reinfused back into thepatient.

The present invention encompasses methods of enhancing antigen-specificT-cell responses by administration of an effective amount of an antigenin a recombinant virus in combination with an immunostimulatory moleculesuch as B7 in a recombinant virus into a mammal. This immunizationapproach augments or enhances immune responses generated by the antigenwith costimulation by the B7 costimulatory molecule. The method ofadministering an antigen containing recombinant virus and a B7containing recombinant virus results in increased antigen specificlymphoproliferation, enhanced cytolytic activity and long lastingimmunity to the antigen as compared to the use of either recombinantvirus alone. In one embodiment of the method of enhancingantigen-specific T-cell responses, mammals, preferably humans, areimmunized with rV-TAA and rV-B7. The ratio of rV-TAA to rV-B7 may bevaried to maximize the antigen-specific T-cell response. Ratios ofrV-TAA to rV-B7 include but are not limited to 1:1, 2:1, 3:1, 4:1, andthe like. The efficacy of the treatment may be monitored in vitro and/orin vivo by determining antigen specific lymphoproliferation,antigen-specific cytolytic response, tumor regression and the like.

The addition of any amount of rV-B7 to an antigen regardless of ratioresults in improved cellular immunity. However, an optimal ratio ofantigen to rV-B7 may be determined for each antigen of interest. In oneembodiment, using a rV-CEA to rV-B7 the ratio resulting in the strongestincrease in antigen specific lymphoproliferative, cytotoxic andantitumor responses specific for CEA was 3:1.

The method of enhancing antigen-specific T-cell responses may be usedfor any antigen. Of particular interest are tumor associated antigensand antigens of infectious agents. In one method of enhancingantigen-specific T-cell responses, rV-CEA and rV-human B7-1 areadministered to a patient bearing a CEA positive carcinoma in an optimalratio to stimulate CEA-specific T-cell responses resulting in reductionor elimination of the CEA positive carcinoma. In another method ofenhancing antigen-specific T-cell responses, rV-gp120 or portionsthereof and rV-human B7-1 are administered to a patient bearing gp120positive cells in a ratio to stimulate gp120 specific T-cell responsesresulting in reduction or elimination of gp120 positive cells.

The present invention also encompasses combination therapy. Bycombination therapy is meant that the composition of a recombinant viruscomprising one or more genes encoding one or more antigens associatedwith one or more disease agents and a recombinant virus comprising oneor more genes encoding one or more immunostimulatory molecules or bothtypes of genes incorporated into the same vector are administered to thepatient in combination with other exogenous immunomodulators orimmunostimulatory molecules, chemotherapeutic drugs, antibiotics,antifungal drugs, antiviral drugs and the like alone or in combinationthereof. Examples of other exogenously added agents include exogenousIL-2, IL-6, interferon, tumor necrosis factor, cyclophosphamide, andcisplatinum, gancyclovir, amphotericin B and the like.

Another aspect of the present invention is a method of treating cancerin which cancer cells are infected with the recombinant virus orcombination of recombinant virus in situ or in vitro. Tumor cellsexpressing both the tumor associated antigen along with animmunostimulatory molecule are administered to a mammal in an effectiveamount to result in tumor reduction or elimination in the mammalafflicted with a cancer.

This invention further comprises an antibody or antibodies elicited byimmunization with the recombinant virus of the present invention. Theantibody has specificity for and reacts or binds with the antigen ofinterest. In this embodiment of the invention the antibodies aremonoclonal or polyclonal in origin.

Exemplary antibody molecules are intact immunoglobulin molecules,substantially intact immunoglobulin molecules or those portions of animmunoglobulin molecule that contain the antigen binding site, includingthose portions of immunoglobulin molecules known in the art as F(ab),F(ab′); F(ab′)₂ and F(v). Polyclonal or monoclonal antibodies may beproduced by methods known in the art. (Kohler and Milstein (1975) Nature256, 495-497; Campbell “Monoclonal Antibody Technology, the Productionand Characterization of Rodent and Human Hybridomas” in Burdon et al.(eds.) (1985) “Laboratory Techniques in Biochemistry and MolecularBiology,” Volume 13, Elsevier Science Publishers, Amsterdam). Theantibodies or antigen binding fragments may also be produced by geneticengineering. The technology for expression of both heavy and light chaingenes in E. coli is the subject of the PCT patent applications:publication number WO 901443, WO 901443 and WO 9014424 and in Huse etal. (1989) Science 246:1275-1281.

In one embodiment the antibodies of this invention are used inimmunoassays to detect the novel antigen of interest in biologicalsamples.

In one embodiment, the CEA antibodies of this invention generated byimmunization with a composition comprising recombinant vaccinia virusexpressing CEA and a recombinant vaccinia virus expressing B7.1 are usedto assess the presence of the CEA antigen from a tissue biopsy of amammal afflicted with a cancer expressing CEA using immunocytochemistry.Such assessment of the delineation of the CEA antigen in a diseasedtissue can be used to prognose the progression of the disease in amammal afflicted with the disease or the efficacy of immunotherapy.Conventional methods for immunohistochemistry are described in (Harlowand Lane (eds) (1988) In “Antibodies A Laboratory Manual”, Cold SpinningHarbor Press, Cold Spring Harbor, N.Y.; Ausbel et al. (eds) (1987). InCurrent Protocols In Molecular Biology, John Wiley and Sons (New York,N.Y.).

In another embodiment the antibodies of the present invention are usedfor immunotherapy. The antibodies of the present invention may be usedin passive immunotherapy.

In providing a patient with the antibodies or antigen binding fragmentsto a recipient mammal, preferably a human, the dosage of administeredantibodies or antigen binding fragments will vary depending upon suchfactors as the mammal's age, weight, height, sex, general medicalcondition, previous medical condition and the like.

The antibodies or antigen-binding fragments of the present invention areintended to be provided to the recipient subject in an amount sufficientto prevent, lessen or attenuate the severity, extent or duration of thedisease or infection.

Anti-idiotypic antibodies arise normally during the course of immuneresponses, and a portion of the anti-idiotype antibody resembles theepitope that induced the original immune response. In the presentinvention, the immunoglobulin gene or portion thereof of an antibodywhose binding site reflects an antigen of a disease state, isincorporated into the genome or portion thereof of a virus genome, aloneor in combination with a gene or portion thereof of an immunostimulatorymolecule, the resulting recombinant virus is able to elicit cellular andhumoral immune response to the antigen.

EXAMPLE 1 Construction and Characterization of Construction of rV-B7-1and rV-B7-2 Materials and Methods

Recombinant Vaccinia Virus

A 1,125 bp DNA fragment encoding the entire open reading frame of murineB7-1 and a 942 bp DNA fragment encoding the entire open reading frame ofmurine B7-2 was amplified by reverse transcriptase PCR (Geneamp RNA PCRKit, Perkin Elmer, Norwalk, Conn.) from total RNA extracted from themurine B-cell line, A20 (TIB 208, ATCC, Rockville, Md.). The sequencesof the B7 inserts were shown to be identical to the published sequences(Freeman, G. J. et al. J. Exp. Med. 174:625-631. 1991; Freeman, G. J. etal. Science 262:813-960, 1993). The DNA fragments were ligatedseparately into the Kpn-1/Xho-1 restriction enzymes sites of thevaccinia virus transfer vector PT116, provided by Therion Biologics(Cambridge, Mass.) which contains the Escherichia Coli Lac Z gene forthe selection of the recombinant viruses. Recombinant viruses werederived as previously described (Kaufman, H. et al. Int. J. of Cancer48:900-907, 1991). Recombinant clones were selected by growth on BSC-1cells (CC126, ATCC) in the presence of 5-bromo-4-chloro-3-indolyl-beta Dgalactosidase (X-Gal). Appropriate blue recombinant clones were purifiedby 5 rounds of plaque purification and grown into a higher titer lysate.Virus for inoculation was grown in spinner cultures of HeLa cells,directly pelleted by centrifugation, and purified over 20%-40% sucrosegradients (Moss, B. Current Protocols in Molecular Biology 2.16.15.1-16.18. 9, 1993).

Characterization of Recombinant Virus

Southern Analysis of DNA Recombination

The recombinant vaccinia genomes were analyzed by viral DNA extraction,restriction endonuclease digestion with Hind III, and Southern blottingas previously described (Kaufman, H. et al. Int. J. Cancer 48:900-907,1991).

Western Analysis of Protein Expression

Confluent BSC-1 cells were infected with either wild-type vaccinia virusor recombinant vaccinia viruses containing the murine B7-1 or B7-2 genes(designated V-Wyeth, rV-B7-1 or rV-B7-2) at an MOI of 10 for 4 hours.Protein was extracted and analyzed as described previously (Kantor, J.et al. J. Nat'l Cancer Inst. 84:1084-1091, 1992). Recombinant B7-1 orB7-2 protein was detected by incubating western blots with anti-B7-1(purified Rat-Anti mouse B7/BB1) or anti-B7-2 (Rat-anti-mouse B7-2(GL-1) monoclonal antibodies (Pharmingen, San Diego, Calif., followed byincubation with Goat-anti-rat conjugated to horseradish peroxidase (HRP,Kirkegaard & Perry Laboratories, Gaithersburg, Md.) and developed as permanufacturers instructions.

Fluorescent Analysis of Protein Expression

Confluent BSC-1cells were infected with either V-Wyeth, rV-B7-1 orrV-B7-2 at 10 MOI for 2 hours. Cells were harvested 3-6 hours postinfection and immunostained with purified Rat-Anti-mouse B7/BB1-FITC orRat-anti-mouse B7-2 (GL-1)-FITC monoclonal antibodies. Cells wereanalyzed by flow cytometry (FACSCAN, Becton Dickinson, San Jose,Calif.).

In-Vivo Experiments

The MC38 murine clonic adenocarcinoma cell line (Fox, B. A. et al. J.Biol. Response Modifiers 9:499-511, 1990) was supplied by the laboratoryof Dr. Steve Rosenberg (National Cancer Institute, Bethesda, Md.). MC38cells were infected with either V-Wyeth, rV-B7-1 or rV-B7-2 at 0.25 MOIfor 1 hour, washed, and suspended in HBSS at a concentration of 3×10⁶cells/ml. Female C57BL/6 mice were obtained from Taconic Farms(Germantown, N.Y.). Six to 8 weeks old animals were given a subcutaneousinjection of 100 μl (3×10⁵ infected cells) in the right flank. Controlmice were injected with uninfected MC38 cells. Mice remaining tumor freefor at least 40 days were challenged on the opposite flank with 3×10⁵uninfected cells. In a parallel experiment, C57BL/6 mice were gammairradiated (500 rad) and injected 24 hours later with either uninfectedMC38 cells, or cells infected with 0.25 MOI V-Wyeth, rV-B7-1 or rV-B7-2.Tumors were measured by caliper in two dimensions, and the volumescalculated as previously described (Kantor, J. et al. J. Nat'l CancerInstit. 84: 1984-1091, 1992).

EXAMPLE 2 Generation and Characterization of Recombinant Virus

The cDNA fragments encoding the open reading frames of murine B7-1 andB7-2 were obtained by reverse transcriptase PCR using B7-1 specificoligonucleotide primers 5′ GGTACCATGGCTTGCAATTGTCAGTTG 3′ (SEQ IDNO.:1), 5′ CTCGAGCTAAAGGAAGACGGTCTG 3′ (SEQ ID No.:2), and B7-2 specificprimers 5′ GGTACCGAAGCACCCACGATGGAC 3′ (SEQ ID No.:3), 5′CTCGAGTCACTCTGCATTTGGTTTTGC 3′ (SEQ ID No.:4) and ligated into thevaccinia virus transfer vector PT116. This vector contains a strongvaccinia virus immediate early promoter (designated P40) upstream of themultiple cloning site to drive the synthesis of the inserted geneproduct. The ligation and orientation of the B7 DNA fragments, as wellas promoter position were verified by PCR and sequencing. The chimericvector construct was inserted into the vaccinia virus genomic Hind III Msite by homologous recombination as previously reported (Kaufman H. etal. Int. J. Cancer 48:900-907, 1991), and confirmed by Southern analyseswith ³²P radiolabeled B7-1 or B7-2 DNA as a probe (data not shown). Theentire cDNA sequences of B7-1 and B7-2 in the vaccinia virus clones wereshown to be identical to the published sequences (Freeman, G. J. et al.J. Exp. Med. 174:625-631, 1991; Freeman, G. J. et al. Science262:813-960; 1993).

Expression of recombinant protein was confirmed by western analysis ofprotein extracts from rV-B7-1 or rV-B7-2 infected BSC-1 cells. Thesecells are routinely used for the evaluation of recombinant vacciniaproducts (Moss, B. Current Protocols in Molecular Biology2.16.15.1-16.18.9, 1993). Incubation of protein extract blots fromrV-B7-1 infected cells with the rat anti-mouse monoclonal antibodyB7-BB1 revealed a broad 50-90 kD band. Similarly, incubation of proteinextract blots from rV-B7-2 infected cells with the rat anti-mousemonoclonal antibody B7-2 (GL-1) revealed a band ranging from 65-100 kD(data not shown). This is (consistent with reports indicating theapparent molecular mass of these molecules, which appear asglycoproteins that are heterogeneous as a result of N-linkedglycosylation (Schwartz, R. H. Cell 71:1065-1068, 1992; Freeman, G. J.et al. J. Exp. Med. 174:625-631, 1991; Freeman, G. J. et al. Science262:813-960, 1993). Uninfected or V-Wyeth infected cells were negativefor the expression of both 117-1 and B7-2.

Cell surface expression of B7-1 or B7-2 recombinant proteins wasexamined by flow cytometry. FIG. 1A illustrates that uninfected BSC-1cells (FIG. 1A) do not react with either B7(BB1) or B7-2 (G1-1)antibodies (98.5% of the cells are negative with a mean fluorescence of5.22). Similarly, cells infected with wild type vaccinia (V-Wyeth, FIG.1B), failed to react with either of these two antibodies (97.7% of thecells are negative with a mean fluorescence of 5.43). BSC-1 cellsinfected with rV-B7-1 (FIG. 1C) react strongly with the B7/BB1 antibody(97.5% of the cells are positive with a mean fluorescence of 2513.68).Cells infected with rV-B7-2 (FIG. 1D) react strongly with the B7-2(G1-1) antibody (98.8% of the cells are positive with a meanfluorescence of 1802.30). There was no reactivity between antibodyB7/BB1 and cells infected with rV-B7-2, and no reactivity of antibodyGL-1 with cells infected with rv-B7-1. These studies thus demonstratethat a recombinant vaccinia virus can express the B7-1 and B7-2molecules on the cell surface at 3-6 hours post infection. Lysis ofinfected cells usually does not occur for 24-48 hours (Moss, B. CurrentProtocols in Molecular Biology 2.16.15.1-16.18.9, 1993).

It has previously been shown that the injection of 3×10⁵ MC38 murineadenocarcinoma cells subcutaneously into syngeneic C57BL/6 routinelygives rise to palpable tumors within 7 to 14 days followed by rapidgrowth that is ultimately fatal (Kantor, J. et al. J. Nat'l Cancer Inst.84:1084-1091, 1992). These tumor cells have also been shown to benegative for the expression of B7 (Chen, L. et al. J. Exp. Med.179:523-532, 1992). To test the recombinant vaccinia constructs for thefunctional expression of B7, the growth of MC38 tumor cells was comparedto that of MC38 infected with rV-B7-1, rV-B7-2, and wild type V-Wyeth(FIGS. 2A-2D). The injection of uninfected MC38 cells (FIG. 2A) resultedin palpable tumors in all animals within 7 days. Tumor growth wasprogressive throughout the duration of this experiment. Animals werekilled in all experiments when any tumor measurement (length or width)exceeded 20 mm. The injection of MC38 cells infected for 1 hour with0.25 MOI V-Wyeth (FIG. 2B) resulted in a slight delay of onset ofpalpable tumor, and all animals eventually became positive for tumor(one animal in FIG. 2B grew an intraperitoneal tumor which could not bemeasured). The MOI of 0.25 was chosen for all groups because infectionswith greater than that amount resulted in higher levels of non-specificcell death resulting in slower tumor growth. The injection of MC38 cellsinfected with 0.25 MOI of rV-B7-1 (FIG. 2C) or rV-B7-2 (FIG. 2D) failedto induce tumors in any mice, which remained tumor free for the durationof this experiment.

Recombinant protein expression of cells infected as this MOI wasconfirmed by flow cytometry. After infection with 0.25 MOI recombinantvirus, approximately 35% of MC38 cells were positive for eitherrecombinant B7-1 or B7-2 with an average mean fluorescence ranging from417-585. MC38 cells either uninfected or infected with 0.25 MOI V-Wyethremained negative for expression of B7-1 or B7-2. These MC38 cells werepositive for the expression of Class I MHC antigen both before and afterinfection. No gross toxic effects were observed in any of these animalsduring the 40 day observation panel. Animal weights remained within onestandard deviation of normal age-matched mice. These experiments wererepeated 3 additional times with similar results.

Studies were conducted to determine whether tumor rejection is dependenton an intact immune system. In these studies, mice were immunosuppressedby radiation (see materials and methods Example 1) and were administeredinfected MC3:8 tumor cells (Table 1). Tumors in irradiated mice infectedwith V-Wyeth, rV B7-1 or rV-B7-2 were measurable 14 days after tumortransplant and no difference in tumor volumes were observed, indicatingthat an intact immune system is necessary to respond to the recombinantB7 molecules.

TABLE 1 Growth of Infected MC38 Tumor In Irradiated Mice (14 Days posttumor transplant) Mean Tumor Volume Infection # Of Animals With Tumor(MM³ ± SEM) MC38 (Wyeth) 5/5 369.9 ± 141.8 MC38 (rV-B7-1) 5/5 441.9 ±204.2 MC38 (rV-B7-2) 5/5 404.0 ± 237.3 Growth of MC38 tumors inimmunocompromised animals. Mice were gamma irradiated and injected withMC38 cells that had been infected for 1 hour with 0.25 MOI of eitherV-Wyeth, rV-B7-1, or rV-B7-2.

In systems using retroviral vectors for introduction of B7 genes, it hasbeen shown that concurrent administration to mice of B7 expressing tumorcells on one flank and administration of B7 negative tumor cells on theopposite flank would prevent the growth of both tumor populations (Chen,L. et al. Cell 71:1093-1102, 1992). In other studies, antitumor activityto B7 negative cells was demonstrated by the multiple intraperitonealinjections of B7 expressing tumor cells ten days following thesubcutaneous administration of B7 negative primary tumor (Li, Y. et al.J. Immunol 153:421-428, 1994). The study described here was designed todetermine if long lasting immunity to tumor cells could be induced byimmunization with rV-B7 infected tumor cells. Mice administered MC38cells infected with rV-B7-1 or rV-B7-2 remained tumor free for in atleast 40 days (FIGS. 2C and 2D)) and were then challenged on theopposite flank with 3×10⁵ uninfected (B7 negative) MC38 cells (FIGS. 3Band 3C). The injection of these MC38 cells into naive mice (FIG. 3A)resulted in palpable tumor formation in all animals within 7 days, withprogressive tumor growth throughout the duration of this experiment.Average tumor volume in this control group at 21 days post tumortransplant was 2436±858 mm³. Mice that had 40 days previously beenadministered tumor infected with rV-B7-1 were also challenged withuninfected MC38 cells (FIG. 3B). The formation of these tumors wasdelayed, and the growth rate was substantially reduced, with an averagetumor volume of 372±106 mm³ at day 21. Similarly, mice that had beenadministered rV-B7-2 infected tumors, when challenged with MC38 cells,displayed a substantial reduction in growth of tumor cells. Averagetumor volume in this group was 197±161 mm³ at day 21. Tumor growth wasthus reduced by >90% in animals previously receiving tumors expressingB7-1 or B7-2 via recombinant vaccinia virus infection. This was ofinterest in light of the fact that only one immunization wasadministered 40 days prior to tumor challenge, and that the mice werechallenged with a relatively large tumor burden. This implies that amemory immune response against a rejection antigen on MC38 tumor cellsis being induced by the injection of rV-B7 infected tumor cells. Theabove method of treatment may be modified to include multipleinoculations with B7 expressing tumor cells, and enhancement of T-cellactivation with immunostimulatory molecules including cytokines such asIL-2.

Previous studies have demonstrated that the introduction of B7 intotumor cells via transduction with retroviral vectors such as PLNSX,PLNCX or PLXSN can confer immunogenicity to those tumors (Chen, L. etal. J. Exp. Med. 179:523-532, 1994; Dohring, C. et al. Int. J. Cancer57:754-759, 1994). These methods of B7 introduction have a potentiallimitation for clinical applications due to a relatively low efficiencyof infection of retroviral vectors and the consequent prolonged amountof time required to drug select and expand the B7 positive tumor cells.As an alternative, the studies reported here have demonstrated thedevelopment of recombinant vaccinia viruses expressing the genes for thecostimulatory molecules B7-1 and B7-2. These recombinant vacciniaconstructs infect tumor cells rapidly (1-4 hours) and expressrecombinant protein with high efficiency (over 97% of cells, FIGS. 1Cand 1D, respectively). Infected cells were shown to authenticallysynthesize the recombinant proteins, leading to antitumor effects. Thesestudies thus present data in an experimental system for the insertion ofB7 genes into vaccinia virus vectors with implications for potentialimmunotherapeutic applications.

EXAMPLE 3 Induction of Ehanced a T-cell Immune Response to a Human TumorAssociated Antigen by Mixing a Recombinant Vaccinia Virus Expressing theTumor Associated Antigen with a Recombinant Vaccinia Virus Expressingthe B7 Co-stimulatory Molecule

The present invention comprises a composition of rV-B7 in combinationwith a recombinant vaccinia virus expressing a human tumor associatedantigen. The composition of the present invention when coinoculated intoa host to enhance the systemic T-cell immune response to that humantumor associated antigen.

Several human tumor associated antigens have now been identified. One ofthese is the human carcinoembryonic antigen (CEA) which is expressed ona range of human carcinomas including colorectal, gastric, pancreatic,breast and non-small cell lung cancers. It have previously been shownthat a recombinant vaccinia CEA construct designated rV-CEA can beadministered to both mice and rhesus monkeys and induce T-cell responsesspecific for CEA in both model systems (Kantor J. et al., J. Natl.Cancer Ins. 84:1084-1091, 1992; Kantor J. et al., Cancer Res.52:6917-6925, 1992). Moreover, no toxicity was observed in eithersystem. Recently, a clinical trial has been completed in which rV-CEAwas administered to patients with metastatic gastrointestinal, breast orlung carcinomas. In this Phase I study, no toxicity other than one wouldobserve with administration of the smallpox vaccine was observed.

One embodiment is the insertion of the B7 and CEA genes into the samerecombinant vaccinia construct since both molecules need to be expressedon the same cell at the same time. Another embodiment is the mixing arV-CEA with a rV-B7 to specifically enhance the T-cell immune responseto CEA. The advantages of this latter approach, is several fold: (a)different ratios of rV-CEA and rV-B7 can be tested to determine theratio for an optimal immune response, (b) the timing of administrationof rV-CEA and rV-B7 can be altered, (c) only one rV-B7 construct needsto be manufactured, i.e., the rV-B7 employed with rV-CEA can also beused with a rV construct to other tumor associated antigens and indeedany other antigen associated with a disease agent for enhancement of animmune response.

In one embodiment, it was demonstrated that simply mixing rV-CEA withrV-B7 and coadministration to the host led to an enhanced T-cell immuneresponse specific for CEA. Moreover, the ratios of rV-CEA to rV-B7 wereimportant factors in the magnitude of the immune response.

In the first study, rV-CEA and rV-B7 were mixed at one to one ratios,i.e., 5×10⁶ pfu of B7 and 5×10⁶ pfu of rV-CEA were mixed andcoadministered to groups of three mice by tail scarification. Spleenswere removed 14 days post-immunization as a source of lymphocytes. Ascontrols, three other groups of mice were used: (a) non-vaccinated mice,(b) mice receiving 5×10⁶ pfu of rV-CEA and 5×10⁶ pfu of wild typevaccinia (designated V-Wyeth), and (c) mice receiving 5×10⁶ pfu ofV-Wyeth and 5×10⁶ pfu of rV-B7. Thus, all vaccinated mice received atotal of 10⁷ pfu of vaccinia virus and in all three groups, ratios ofvaccinia viruses were 1 to 1. As can be seen in FIG. 4, after oneadministration of rV-CEA plus V-Wyeth, mice did mount an immune responsespecific for CEA, albeit low. The immune assay employed was alymphoproliferative assay which as been described previously (Kantor etal., J. Natl. Cancer Inst., 84:1084-1092, 1992) and the target antigenused was recombinant CEA derived from baculovirus. As can be seen inFIG. 4, the addition of rV-B7 to rV-CEA enhanced the specific immuneresponse several fold. In contrast, the addition of rV-B7 to the controlV-Wyeth had no effect on enhancing the CEA specific immune response.

In the next study the ratio of rV-CEA to rV-B7 was modified to that of 1to 3. As shown in FIG. 5, the administration of rV-CEA plus rV-B7 at the1:3 ratio enhanced the CEA specific T-cell response as compared torV-CEA plus V-Wyeth, and to a greater extent than when the twoconstructs (rV-B7 plus rV-CEA) were mixed at a 1:1 ratio. Again, the twocontrol groups, i.e., no vaccination and rV-B7 mixed with V-Wyeth showedno immune response to CEA.

These results indicate that simply mixing a rV-containing a humanassociated gene with rV-B7 can lead to coinfection and coexpression onantigen presenting cells so as to enhance specific T-cell responses forthe human tumor associated antigen. Moreover, it appears that the ratiosof rV-B7 and the rV-containing human associated gene used may be animportant factor in optimizing T-cell activation to a human tumorassociated gene product or indeed any other gene product one wished to,induce or enhance immunity to.

EXAMPLE 4 Lymphoproliferative Responses of Mouse T-cells to CEA AfterImmunization with rV-CEA+rV-B7

Lymphoproliferative Responses

C57BL/6 mice were immunized with 1×10⁷ PFU total virus with variousratios of either: V-Wyeth; rV-CEA:V-Wyeth; Wyeth:rV-B7; or rV-CEA:rV-B7,and CEA specific lymphoproliferation was analyzed as previouslydescribed (Kantor, J. et al J. Nat'l Cancer Inst. 84:1084-1091, 1992).Briefly, spleens were removed 14 days following immunization andmechanically dispersed through 70 μm cell strainers (Falcon, BectonDickinson, Franklin Lakes, N.J.) to isolate single cell suspensions.Erythrocytes and dead cells were removed by centrifugation over aFicoll-Hypaque gradient (density=1.119 g/ml) (Sigma Chemical Co., St.Louis, Mo.). Populations consisting of approximately 95% T-cells wereobtained by passage of splenic mononuclear cells over nylon wool columns(Robbins Scientific Corp., Sunnyvale, Calif.). To evaluate CEA specificlymphoproliferation, T-cells were added at 10⁵/well in 96 well flatbottomed plates (Costar, Cambridge, Mass.). Antigen presenting cellsconsisted of irradiated (2000 rads) naive syngeneic splenocytes added at5×10⁵/well. Stimulated wells received purified human CEA (100-12.5μg/ml) (Vitro Diagnostics, Denver, Colo.); ovalbumin as a negativecontrol (100 μg/ml); UV-inactivated V-Wyeth (2×10⁷ PFU/ml) as a recallantigen or Con-A. (2 μg/ml) as a T-cell positive control. Control wellsreceived T-cells, APC's and media only. Cells in all wells were culturedin a total volume of 200 μof complete media (CM), [RPMI 1640 with fetalcalf serum (10%); glutamine (2 mM), sodium pyruvate (1 mM), Hepes (7mM), gentamicin (50 μg/ml), 2-mercaptoethanol (50 μM), and non-essentialamino acids (0.1 mM), (Biofluids, Rockville, Md.)] for 5 days. Cellswere labeled for the final 12-18 h of the incubation with 1 μCi/well[³H]thymidine (New England Nuclear, Wilmington, Del.) and harvested witha PHD cell harvester (Cambridge Technology, Cambridge, Mass.). Theincorporated radioactivity was measured by liquid scintillation counting(LS 6000IC; Beckman, Duarte, Calif.). The results from triplicate wellswere averaged and are reported as stimulation index (SI) as calculated:SI=[CPM (stimulated wells)]/[CPM (control wells)].

Lymphoproliferative Analysis

To determine if immunization with an admixture of rV-CEA and rV-B7 couldresult in enhanced CEA specific lymphoproliferative responses, C57BL/6mice were immunized one time with a total of 10⁷ PFU of rV-CEA:V-Wyeth,V-Wyeth:rV-B7, or rV-CEA:rV-B7, at either 1:1, 1:3, or 3:1 ratios (seeTable 2) and lymphoproliferative responses were analyzed after 14 days.Table 2 shows that T-cells from mice receiving no immunization failed torespond to purified CEA, while T-cells from mice immunized withrV-CEA:V-Wyeth responded weakly (stimulation index [SI] of 1.9-2.5). Theresponse to CEA appeared to be related to the dose of rV-CEA givenduring the immunization. T-cells from mice immunized with all ratios ofV-Wyeth:rV-B7 failed to respond to CEA. In contrast, T-cells from miceimmunized with any ratio of rV-CEA:rV-B7 appeared to have an increasedresponse to CEA in comparison to the cohorts receiving no rV-B7 withtheir immunization (Table 2). The immunization of rV-CEA:rV-B7 (3:1) wasoptimal for induction of lymphoproliferation in this experiment (SI of12.3). Experiment in which rV-CEA:rV-B7 ratios were altered (3:1, 1:1,1:3) were conducted 4 times, and in each case the 3:1 ratio provided thegreatest increase in CEA specific T-cell responses, To further examinethe extent of the CEA specific cellular immune response, mice wereimmunized one time with rV-CEA:V-Wyeth (3:1); V-Wyeth:rV-B7 (3:1); orrV-CEA:rV-B7 (3:1) and lymphoproliferative responses were analyzed asbefore.

TABLE 2 Lymphoproliferative Responses of Mouse T-cells to CEA afterImmunization with Various Ratios of rV-CEA + rV-B7 Ratio Antigen^(b)Immunogen^(a) (1 × 10⁷ total) Con A Oval CEA No Immunization NA^(c) 3591.0 1.4 rV-CEA/V-Wyeth 1:1 312 1.7 2.1 rV-CEA/V-Wyeth 1:3 284 0.9 1.9rV-CEA/V-Wyeth 3:1 442 1.0 2.5 V-Wyeth/rV-B7 1:1 359 1.0 1.7V-Wyeth/rV-B7 1:3 412 1.9 1.6 V-Wyeth/rV-B7 3:1 387 1.8 0.4 rV-CEA/rV-B71:1 403 1.4  7.0 ^(d) rV-CEA/rV-B7 1:3 394 1.0 4.0 rV-CEA/rV-B7 3:1 3451.8 12.3  ^(a)5 C57BL/6 mice were immunized one time as indicated.Lymphoproliferative responses from pooled splenic T-cells were analyzed14 days following immunization. ^(b)Antigen concentrations were: Con A(2 μg/ml); ovalbumin (100 μg/ml); and CEA (100 μg/ml). Each valuerepresents the stimulation index of the mean CPM of triplicate samplesversus media. Standard deviation never exceeded 10%. ^(c)NA, Notapplicable. ^(d)Values in bold are significant when compared to theirrespective medium control values (p < 0.001).

Table 3 shows that T-cells from mice receiving no immunization failed torespond to purified CEA at any concentration, or to UV-inactivatedV-Wyeth. T-cells from mice immunized with V-Wyeth responded toUV-V-Wyeth with a strong stimulation index (31.7), while failing toproliferate in response to CEA. In contrast, T-cells from mice immunizedwith rV-CEA:V-Wyeth (3:1) proliferated when cultured with CEA in a dosedependent manner (stimulation index of 4.5-1.6). T-cells from miceimmunized only with rV-B7 (V-Wyeth:rV-B7) failed to respond to CEA.Finally, T-cells from mice immunized with the combination of rV-CEA andrV-B7 (3:1) proliferated in response to CEA antigen in a dose dependentmanner (SI=18.6-3.0). This stimulation index represents a greater than4-fold increase in CEA specific proliferative responses following theaddition of rV-B7. T-cells from every group responded to the controllymphocyte mitogen Con A, and failed to react with the negative controlantigen ovalbumin.

TABLE 3 Lymphoproliferative Responses of Mouse T-cells to CEA afterImmunization with 3:1 Ratio of rV-CEA + rV-B7 Ratio (1 × 10⁷ UV CEA(μg/ml) Immunogen^(a) total) Con A Oval V-Wyeth 100 50 25 12.5 No NA^(c) 456 1.0 1.1 2.2 1.4 0.9 0.6 Immunization V-Wyeth/V- NA 471 1.731.7 2.2 2.8 2.2 1.9 Wyeth rV-CEA/V- 3:1 451 1.0 35.4 4.5 3.6 2.5 1.6Wyeth V-Wyeth/rV-B7 3:1 345 1.8 42.0 1.4 0.4 0.0 0.0 rV-CEA/rV-B7 3:1395 1.9 40 18.6 ^(d) 7.2 6.5 3.0 ^(a)5 C57BL/6 mice were immunized onetime as indicated. Lymphoproliferative responses from pooled splenicT-cells were analyzed 14 days following immunization. ^(b)Antigenconcentrations were: Con A (2 μg/ml); Ovalbumin (100 μg/ml); UV-Wyeth (2× 10⁷ pfu/ml); and CEA (100 − 12.5 μg/ml). Each value represents thestimulation index of the mean CPM of triplicate samples versus media.Standard deviation never exceeded 10%. ^(c)NA, Not applicable.^(d)Values in bold are significant when compared to their respectivemedium control values (p < 0.001).

EXAMPLE 5 Dual Expression of Both CEA and B7-1 on Cells Infected withrV-CEA and rV-B7

Flow Cytometry Methods

Two color flow cytometry was used to demonstrate dual infection of cellsin-vitro with RV-CEA and rV-B7. Confluent BSC-1 cells (CCI 26, ATCC,Rockville, Md.) were infected for 2 hours with a 3:1 mixture of eitherrV-CEA:rV-B7, rV-CEA:V-Wyeth, V-Wyeth:rV-B7, or V-Wyeth alone, at atotal MOI of 5. Cells were harvested 18 h post infection and stainedwith a combination of PE-conjugated rat anti-mouse B7-1 mAb (Pharmingen,San Diego, Calif.) and FITC-conjugated anti-CEA mAb COL-1 (36) or FITC-and PE-conjugated isotype-matched control mAb (Pharmingen). The COL-1mAb was conjugated to FITC using a standard method (37). Cellfluorescence was analyzed by using a FACSCAN (Becton Dickinson, MountainView, Calif.) with the Lysis II software.

Flow Cytometric Analysis: Dual Expression of Recombinant CEA and B7

Because it has been proposed that both antigen and B7-1 must beexpressed in close proximity to each other to properly co-engage theT-cell and CD28 receptors (Jenkins, M. K. et al Current Opinion inImmunol. 5:361-367, 1993; Hathcock, K. S. et al J. Exp. Med.180:631-640, 1994; Hellstrom, K. E. et al Ann. NY Acad. Sci.690:225-230, 1993: Harding, F. A. et al J. Exp. Med. 177:1791-1796,1993), it was determined whether infection of cells with a mixture ofrV-CEA and rV-B7 would lead to dual expression of both CEA and B7-1 onthe cell surface. To determine dual expression, BSC-1 cells wereinfected with a 3:1 mixture of rV-CEA:V-Wyeth, V-Wyeth:rV-B7, orrV-CEA:rV-B7 or V-Wyeth alone, and analyzed by two color flow cytometry.Cells infected with V-Wyeth:V-Wyeth demonstrated only background levelsof staining (FIG. 6A); whereas cells infected with rV-CEA:V-Wyeth werepositive principally for CEA (FIG. 6B). Similarly, cells infected withthe mixture of V-Wyeth:rV-B7 were positive principally for B7-1 (FIG.6C). Cells co-infected with rV-CEA:rV-B7, however, were positive forboth CEA and B7-1 (FIG. 6D).

EXAMPLE 6 Increased CEA Specific Cytotoxicity Following Immunizationwith rV-CEA:rV-B

Cytolytic Response Methods

Mice were immunized as described in Example 4 and CEA specific cytolyticactivity was analyzed as previously described (Kantor, J. et al J. Nat'lCancer Insti. 84:1084-1091. 1992). Briefly, spleens were removed 14 daysfollowing immunization, dispersed into single cell suspensions, and runover Ficoll-Hypaque gradients. The MC38 murine colonic adenocarcinomacell line (Fox, B. A. et al J. Bio. Resp. Modifiers 9:499-511, 1990) wassupplied by the laboratory of Dr. Steve Rosenberg (National CancerInstitute, Bethesda, Md.). The derivative cell line expressing humanCEA, MC-38-CEA-2, has been described (Robbins, P. F. et al Cancer Res.51:3657-3662, 1991). These tumor cells were prepared for use as targetsin a standard cytolytic assay (Wunderlich, J. et al Current Protocols inImmunology, Colligan, J. E. et al (eds) 3.11.1-3.11.14, 1994) utilizing¹¹¹In. Briefly, tumor cells (1-2×10⁶) were radiolabeled with 50 μCi of¹¹¹In Oxyquinoline solution (Amersham, Arlington Heights, Ill.) for 20min at 37° C. followed by thorough washing to remove unincorporatedradionuclide. Splenic lymphocytes and targets (5×10³ cells/well) weresuspended in CTL medium (complete medium with RPMI-1640:EHAA 50:50,Biowhittaker, Walkersville, Md., substituted for the RPMI-1640) andcombined at effector-to-target ratios of 100:1 to 12.5:1 in 96 well Ubottomed plates (Costar) and incubated for 16 hours at 37° C. with 5%CO₂. After incubation, supernatants were collected using a SupernatantCollection System (Skantron, Sterling, Va.) and radioactivity wasquantitated using a gamma counter. (Cobra Autogamma, Packard, DownersGrove, Ill.). The percentage of specific release of ¹¹¹In was determinedby the standard equation: % specificlysis=[(experimental-spontaneous)/(maximum-spontaneous)]×100.

Cytotoxic T-cell Analysis: Increased CEA Specific Cytotoxicity FollowingImmunization with rV-CEA:rV-B7

To analyze the effect of the addition of rV-B7 to rV-CEA on CEA specificcytotoxic activity, splenic lymphocytes from mice immunized with themixture of rV-B7 and rV-CEA were tested for lytic activity with murineadenocarcinoma cells that were negative for CEA (MC38) or the same cellstransduced with CEA using a retroviral vector to express human CEA(MC-38-CEA-2). FIG. 7 demonstrates that T-cells from mice immunized onetime with rV-CEA:V-Wyeth (3:1) did not lyse the CEA negative MC38targets, (closed triangles), but did lyse the CEA positive MC-38-CEA-2targets (open triangles) albeit at a low level. This CEA specific lysiswas E:T ratio dependent, with lysis declining to 10% at the E:T ratio of12.5:1. The addition of rV-B7 to the immunogen rV-CEA (rV-CEA:rV-B7;3:1) had no effect on the lysis of MC38 cells (closed circles), but hada substantial effect on CEA specific lysis of MC-38-CEA-2 targets. Basedon conversion of data to lytic units, CTL activity from mice immunizedwith rV-CEA:rV-B7 (3:1) exhibited a 2.8 fold increase when compared tomice immunized with rV-CEA alone.

EXAMPLE 7 Anti-Tumor Effects of rV-B7 Admixed with rV-CEA

Method

Ten C57BL/6 mice were immunized with 1×10⁷ PFU total virus. Fourteendays following immunization, the mice were given a subcutaneousinjection of 3×10⁵ MC-38-CEA-2 cells in the right flank. Mice from therV-CEA:rV-B7 (3:1) group remaining tumor free for at least 60 days werechallenged on the opposite flank with 3×10⁵ MC-38-CEA-2 cells. Tumorswere measured by caliper in two dimensions, and the volumes calculatedas previously described (Kantor, J. et al J. Nat'l Cancer Inst.84:1084-1091, 1992). Animals were sacrificed in all experiments when anytumor measurement (length or width) exceeded 20 mm.

Antitumor Effects of rV-B7 Admixed with rV-CEA

It has been previously shown that the administration of 3×10⁵MC-38-CEA-2 murine adenocarcinoma cells subcutaneously into syngeneicC57BL/6 mice gives rise to palpable tumors within 7-14 days followed byrapid tumor growth that is ultimately fatal (Kantor, J. et al J. Nat'lCancer Inst. 84:1084-1091, 1992). It has also been shown that 3immunizations with 1×10⁷ PFU rV-CEA is required to protect 100% or micefrom this tumor challenge (Kantor, J. et al J. Nat'l Cancer Inst. 84:1084-1091, 1992). To determine if immunization with the 3:1 ratio ofrV-CEA and rV-B7 could protect animals from tumor challenge, we comparedthe growth of MC-38-CEA-2 tumor cells in C57BL/6 mice immunized only onetime with a total of 10⁷ PFU of either V-Wyeth, rV-CEA:V-Wyeth (3:1);V-Wyeth:rV-B7 (3:1); or rV-CEA:rV-B7 (3:1). The injection of MC-38-CEA-2cells (FIG. 8A) resulted in palpable tumors in all ten V-Wyeth immunizedanimals within 14 days. Tumor growth was progressive throughout theduration of this experiment. The injection of MC-38-CEA-2 cells intoanimals immunized with rV-CEA:V-Wyeth (3:1; FIG. 8B) resulted in aslight delay of onset of palpable tumor, and 70% of animals eventuallybecame positive for tumor. The injection of MC-38-CEA-2 cells intoanimals immunized with Wyeth:rV-B7 (3:1; FIG. 8C) resulted in palpabletumors in 14 days with tumor growth closely resembling the V-Wyethimmunized control group (FIG. 8A). In contrast, 80% of mice immunizedone time with rV-CEA:rV-B7 (3:1; FIG. 8D) failed to develop tumors.Tumor negative mice (n=8) remained tumor free for the duration of thisexperiment (60 days). No gross toxic effects were observed in any ofthese animals during the observation period. Animal weights remainedwithin one standard deviation of normal age-matched mice. Theseexperiments were repeated 3 additional times with similar results.

To determine if long lasting immunity to tumor cells could be induced byimmunization with this combination of rV-CEA:rV-B7 (3:1), mice immunizedwith this ratio of recombinant viruses, which remained tumor free for atleast 60 days (FIG. 8D), were then re-challenged on the opposite. flankwith 3×10⁵ MC-38-CEA-2 cells (FIG. 9B). The injection of MC-38-CEA-2cells into control naive mice (FIG. 9A) resulted in palpable tumorformation in all animals within 14 days, with progressive tumor growththroughout the duration of this experiment, whereas mice previouslyadministered rV-CEA:rV-B7 (3:1) did not develop tumors throughout theadditional 49 day observation period (FIG. 9B).

EXAMPLE 8 Construction and Characterization of rV-PSA

Recombinant Vaccinia Virus

A 786 bp DNA fragment encoding the entire open reading frame of humanprostate specific antigen was amplified by reverse transcriptase PCR(GeneAmp RNA PCR Kit, Perkin Elmer, Norwalk, Conn.) from total RNAextracted from the human metastatic prostate adenocarcinoma cell line,LNCaPFGC (CRL 1740, American Type Culture Collection (ATCC), Rockville,Md.). The predicted amino acid sequence derived from the PSA codingsequence was shown to be nearly identical to the published sequence(Lundwall et al, FEBS Letters 214:317-322, 1987) differing only in achange from asparagine to tyrosine at position 220. The PSA DNAfragment, containing the entire coding sequence for PSA, 41 nucleotidesof the 5′ unstranslated region, and 520 nucleotides of the 3′untranslated region, was ligated into the Xba I restriction enzyme siteof the vaccinia virus transfer vector pT116. The resulting plasmid,designated pT1001, contained the PSA gene under the control of thevaccinia virus 40K promoter (Gritz et al, J. Virology 64:5948-5957,1990) and the Escherichia coli Lac Z gene under the control of thefowlpox virus C1 promoter (Jenkins et al, AIDS Research and HumanRetroviruses 7:991-998, 1991). The foreign genes were flanked by DNAsequences from the Hind III M region of the vaccinia genome. Aplaque-purified isolate from the Wyeth (New York City Board of Health)strain of vaccinia was used as the parental virus in the construction ofrecombinant vaccinia virus. The generation of recombinant virus wasaccomplished via homologous recombination between vaccinia sequences inthe Wyeth vaccinia genome and the corresponding sequences in pT1001 invaccinia infected RK₁₃ cells (CCL 37, ATCC) transfected with pT1001.Recombinant clones were identified and selected by growth on RK₁₃ cells(CCL 37, ATCC) in the presence of5-bromo-4-chloro-3-indoly-beta-D-galactopyranoside (X-Gal) as describedpreviously (Panicali et al, Gene 47:193-199, 1986; Kaufman et al, Int.J. Cancer 48:900-907, 1991). Appropriate blue recombinant clones werepurified by four rounds of plaque purification. Virus stocks wereprepared by clarifying infected RK₁₃ cell lysates followed bycentrifugation through a 36% sucrose cushion.

Southern Analysis of DNA Recombination

The recombinant vaccinia genome was analyzed by viral DNA extraction,restriction endonuclease digestion with Hind III and Cla I, and Southernblotting as previously described (Kaufman et al, Int. J. Cancer48:900-907, 1991).

Western Analysis of PSA Protein Expression

Confluent BSC-40 cells were infected with either parental wild typevaccinia virus (designated V-Wyeth) or recombinant vaccinia-PSA(designated rV-PSA) at an MOI of 1 in Dulbecco's Modified Eagle's Mediumcontaining 2% fetal bovine serum. After an overnight infection, themedium was removed from the cells, and an aliquot was methanolprecipitated to assay for the presence of secreted PSA. The infectedcells were lysed in hypotonic lysis buffer (150 mM NaCl, 0.05% EDTA, 10mM KCl, 1 mM PMSF) and then sonicated. Cell lysates and culture mediawere electrophoresed on an SDS-10% acrylamide gel. The proteins weretransblotted to nitrocellulose, and the blot was incubated with a rabbitantibody specific for PSA (PO798, Sigma Chemical Co., St. Louis, Mo.)for 4 hours at ambient temperature, washed, and then incubated with goatanti-rabbit phosphatase-labeled secondary antibody (AP, Kirkegaard &Perry Laboratories, Gaithersburg, Md.) and developed according to themanufacture's instructions.

Characterization of Recombinant Virus (rV-PSA)

The cDNA fragment encoding the open reading frame of human PSA wasobtained by reverse transcriptase PCR using PSA specific oligonucleotideprimers 5′ TCTAGAAGCCCCAAGCTTACCACCTGCA 3′(SEQ ID NO:5)5′TCTAGATCAGGGGTTGGCCACGATGGTGTCCTTGATCCACT 3′(SEQ ID NO:6) and ligatedinto vaccinia virus transfer vector pT116. This vector contains a strongvaccinia virus early/late promoter (designated 40K) upstream of themultiple cloning site to drive the synthesis of the inserted geneproduct. The ligation and orientation of the PSA DNA fragment, as wellas promoter position were verified by PCR and sequencing. The chimericvector construct was inserted into the vaccinia virus genome Hind III Msite by homologous recombination as previously reported (Kaufman et al,Int. J. Cancer, 48:900-907, 1991) and confirmed by Southern analysisprobing with ³²P radiolabeled DNA corresponding to PSA sequences andvaccinia sequences in the Hind III M region (data not shown).

Expression of recombinant PSA protein was confirmed by western blotanalysis of supernatant fluids and protein extracts from rV-PSA infectedBSC 40 cells. These cells are routinely used for the evaluation ofrecombinant vaccinia products (Earl et al, Current Protocols inMolecular Biol., 2.16.15.1-16.18.9, 1993). Incubation of cellsupernatant blots from rV-PSA infected cells with rabbit anti-PSAantibody revealed a single immunoreactive polypeptide of approximately33,000 daltons (data not shown). Similarly, incubation of proteinextract blots from rV-PSA infected cells revealed a single band of thesame molecular weight (data not shown). This is consistent with thepredicted size of the PSA molecule (Armbruster et al, Clin. Chem.39:181-195, 1993; Wang et al Methods in Cancer Research, 19:179-197,1982). Cell supernatant blots or protein extract blots from cellsinfected with parental strain V-Wyeth remained negative for expressionof PSA. These results thus demonstrate that a recombinant vaccinia viruscan faithfully express the human PSA gene product.

EXAMPLE 9 Increased PSA Specific Cytotoxicity Following Immunizationwith rV-PSA:rV-B7

Cell Lines

MC-38, a murine colonic adenocarcinoma cell line (Fox, B. A. et al J.Biol. Response Mod. 9:499-511, 1990) was obtained from Dr. Bernard Fox(National Cancer Institute, National Institutes of Health, Bethesda,Md.). The LNCaP human prostate adenocarcinoma cell line (Horoszewicz, J.S. et al In: Murphy, G. P. (ed.) Models for Prostate Cancer, pp.115-132, New York: A. R. Liss, 1980) was obtained from the American TypeCulture Collection (Rockville, Md.). The Moloney murine sarcoma virusretroviral vector pLNSC (Miller, A. D. et al Biotechniques 7:980-990,1989) was obtained from Dr. A. Dusty Miller (Fred Hutchinson CancerResearch Center, Seattle, Wash.). The murine ecotropic packaging cellline GP+E-86 (Hesdorffer, C. Hematol. Oncol. Clin. North Am.5(3):423-432, 1991), MC-38, PSA/MC-38 and pLNSX/MC-38 were maintained inDulbecco's modified Eagle medium (DMEM) (Gibco BRL, Gaithersburg, Md.)with 10% fetal bovine serum (FBS) (Gibco BRL). PSA/MC-38 and pLNSX/MC-38cell lines were kept under continuous selective pressure in 1 mg G418sulfate/ml (Gibco BRL). LNCaP was maintained in RPMI-1640 medium (GibcoBRL) containing 10% FBS.

Cloning of PSA cDNA

Complementary DNA (cDNA) was synthesized from total RNA from the humanprostate adenocarcinoma cell line LNCaP using the GeneAmp RNA polymerasechain reaction (PCR) Kit (Perkin Elmer Corp., Norwalk, Conn.). HumanPSA-specific oligonucleotide primers were selected based on the humanmRNA sequence (GenBank accession number X07730) using the MacVector4.1.4. computer program (Kodak Co., Rochester, N.Y.). The 5′(5′ AGA GAGAGC CTC AAG CTT CAG CCC CAA GCT TAC CAC CTG CA 3′)(SEQ ID NO:7) and3′(5′ AGA GAG AGC AAG CTT AGT CCC TCT CCT TAC TTC AT 3′)(SEQ ID NO:8)primers, containing HindIII restriction enzyme sites, were used tosynthesize full-length PSA cDNA by PCR. The 1.5-kb PSA gene was ligatedto HindIII restriction endonuclease-digested pLNSX DNA and was used totransform competent CH5α Escherichia coli cells (Gibco BRL).Ampicillin-resistant colonies were tested for orientation of the cDNAinsert by PCR using a vector-specific 5′ oligonucleotide primer (5′ TTTGGA GGC CTA GGC TTT TGC AAA 3′)(SEQ ID NO: 9) and the PSA-specific 3′primer described above. Transformants were selected with PSA cDNA in thesense orientation, characterized by restriction endonuclease digestion,and sequenced by the dideoxy method using Sequenase (United StatesBiochemical Corp., Cleveland, Ohio). Sequence analysis of the generecovered by PCR confirmed that the gene was identical to the human PSAgene sequence in GenBank.

Transfection and Transduction of DNA into Target Cells, MC-38

The PSA/pLNSX plasmid (5 μg) was transfected into MC-38 cells usingTransfection-reagent (DOTAP) (Boehringer Mannheim Biochemica,Indianapolis, Ind.) according to the manufacturer's instructions. At 24h, selection medium containing 100 μg/ml (wt/vol) of G418 was added tothe cells. Selective pressure was maintained by continuous culture inDMEM containing 10% FBS and increasing concentrations of G418 (to 1mg/ml). Drug-resistant cells were cloned by limiting dilution.Conditioned medium from the cloning walls was tested using the solidphase, double-determinant Tandem-R PSA immunoradiometric assay(Hybritech Inc., San Diego, Calif.). The highest producers of secretedPSA were cloned twice by limiting dilution. One clone, designatedPSA/MC-38, produced approximately 10 ng PSA/ml.

Vector-transduced, PSA-negative MC-38 cells were developed as follows.GP+E+86 cells, an ecotropic murine packaging cell line, were transfectedwith 2 μg of pLNSX vector DNA using DOTAP transfection-reagent, asdescribed above. At 24 h the transfected cells were replated and grownin selection medium (1.0 mg G418/ml). Cells surviving G418 selection andcontaining pLNSX were grown in medium without G418, and this medium wasadded to MC-38 cells in the presence of 8 μg/ml of polybrene (SigmaChemical Co., St. Louis, Mo.). The transduced MC-38 cells were grown inthe presence of G418 for 3 weeks. Individual drug-resistant colonieswere isolated by sterile cloning rings and characterized by PCR for thepresence of pLNSX. One clone, pLNSX/MC-38, was used for further study.

Cytolytic Response Methods

Mice were immunized with rV-PSA using the basic protocol as described inExample 6. The source of rV-PSA, made as described in Example 8, wasTherion Biologics Corporation, Cambridge, Mass. The MC38 murine colonicadenocarcinoma cell line expressing human PSA (MC38-PSA) as describedabove and in Karr, J. F. et al (Cancer Research, in press) was used asthe antigen specific target.

Cytotoxic T-cell Analysis: Increased PSA Specific Cytotoxicity FollowingImmunization with rV-PSA:rV-B7

To analyze the effect of the addition of rV-B7 to rV-PSA on PSA specificcytotoxic activity, splenic lymphocytes from mice immunized with themixture of rV-B7 and rV-PSA were tested for lytic activity with murineadenocarcinoma cells that were negative for PSA (MC38) or the same cellstransduced with PSA (MC38-PSA). FIG. 10 demonstrates that T-cells frommice immunized one time with rV-PSA did not lyse PSA negative MC38targets, but did lyse the PSA positive MC38-PSA targets. The addition ofrV-B7 to the immunogen rV-PSA had no effect on the lysis of MC38 cellsbut had a substantial effect on PSA specific lysis of MC38-PSA targets(FIG. 10). The specificity of the lysis was further demonstrated asT-cell from mice immunized with a different antigen, rV-CEA:B7-1 did notlyse MC38-PSA targets.

EXAMPLE 10 Use of Lymphocytes Sensitized to Immunogenic Peptides Derivedfrom CEA Antigens for Therapeutically Treating Mammals Afflicted withCancer

T-lymphocytes presensitized to the CEA antigen may be effective intherapeutically treating mammals afflicted with cancer. T-lymphocytesfrom peripheral blood or tumor suspensions and cultured in vitro(Kawakami, Y. et al. (1988) J. Exp. Med. 168:2183-2191). TheT-lymphocytes are exposed to cells infected with the recombinant virusexpressing a CEA associated antigen and/or recombinant virus expressingB7.1 and/or B7.2 for a period of about to 1-16 hours at a concentrationof 1-10 MOI. T-lymphocytes exposed to the antigen will be administeredto the mammal, preferably a human at about 10⁷-10¹² lymphocytes. Thelymphocytes may be administered either intravenously, intraperitoneallyor intralesionally. This treatment may be administered concurrently withother therapeutic treatments such as cytokines, radiotherapy, surgicalexcision of tumor lesions and chemotherapeutic drugs, adoptive Tlymphocyte therapy.

While the invention is described above in relation to certain specificembodiments, it will be understood that many variations are possible,and that alternative materials and reagents can be used withoutdeparting from the invention. In some cases such variations andsubstitutions may require some experimentation, but will only involveroutine testing.

The foregoing description of the specific embodiments will so fullyreveal the general nature of the invention that others can, by applyingcurrent knowledge, readily modify and/or adapt for various applicationssuch specific embodiments without departing from the generic concept,and therefore such adaptations and modifications are intended to becomprehended within the meaning and range of equivalents of thedisclosed embodiments.

All references and patents referred to are incorporated herein byreference.

9 27 base pairs nucleic acid single linear other nucleic acid Yes No 1GGTACCATGG CTTGCAATTG TCAGTTG 27 24 base pairs nucleic acid singlelinear other nucleic acid Yes No 2 CTCGAGCTAA AGGAAGACGG TCTG 24 24 basepairs nucleic acid single linear other nucleic acid Yes 3 GGTACCGAAGCACCCACGAT GGAC 24 27 base pairs nucleic acid single linear othernucleic acid Yes No 4 CTCGAGTCAC TCTGCATTTG GTTTTGC 27 28 base pairsnucleic acid single linear other nucleic acid Yes No 5 TCTAGAAGCCCCAAGCTTAC CACCTGCA 28 41 base pairs nucleic acid single linear othernucleic acid Yes No 6 TCTAGATCAG GGGTTGGCCA CGATGGTGTC CTTGATCCAC T 4141 base pairs nucleic acid single linear other nucleic acid Yes No (R) 7AGAGAGAGCC TCAAGCTTCA GCCCCAAGCT TACCACCTGC A 41 35 base pairs nucleicacid single linear other nucleic acid Yes No 8 AGAGAGAGCA AGCTTAGTCCCTCTCCTTAC TTCAT 35 24 base pairs nucleic acid single linear othernucleic acid Yes No 9 TTTGGAGGCC TAGGCTTTTG CAAA 24

What is claimed is:
 1. A host cell infected with a recombinant vacciniavirus which has incorporated into a viral genome, at a region selectedfrom the group consisting of Hind III F, F13L, HA, Hind III M, and TK,one or more genes or portion thereof encoding an antigen of a diseasestate and a gene or portion thereof encoding B7.2, or B7.1 and B7.2,resulting in coexpression of genes encoding the antigen of a diseasestate and genes encoding B7.2, or B7.1 and B7.2.
 2. The host cell ofclaim 1 wherein the antigen is a tumor associated antigen.
 3. The hostcell of claim 2 wherein the tumor associated antigen is selected fromthe group consisting of oncofetal antigens, MART-1, Mage-1, Mage-3,gp100, tyrosinase, CEA, PSA, CA-125, erb-2, Muc-1, Muc-2, point mutatedras oncogenes, point mutated p53 oncogenes and TAG-72.
 4. The host cellaccording to claim 1 wherein the recombinant virus further comprisingone or more genes or portion thereof encoding an immunostimulatorymolecule selected from the group consisting of IL-2, ICAM-1, LFA-3,CD72, GM-CSF, TNFα, INFγ, IL-12, IL-6 and combinations thereof.
 5. Thehost cell according to any one of claims 1 to 4 wherein the host cell isan antigen presenting cell, a tumor cell, a cell infected with apathogenic microorganism, or a genetically deficient cell.
 6. The hostcell of claim 5, wherein the antigen presenting cell is a dendritic cellor macrophage.
 7. A pharmaceutical composition comprising the host cellaccording to claim 5 alone or in combination with an exogenousimmunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviraldrug or anti-fungal drug and a pharmaceutically acceptable carrier.
 8. Apharmaceutical composition comprising the host cell according to any oneof claims 1 to 4 and a pharmaceutically acceptable carrier.
 9. Thepharmaceutical composition according to claim 8 further comprising anexogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic,antiviral drug or anti-fungal drug.